This company is no longer active
InDex Pharmaceuticals Holding Toekomstige groei
Future criteriumcontroles 0/6
InDex Pharmaceuticals Holding's earnings are forecast to decline at 48.5% per annum. EPS is expected to decline by 47.7% per annum.
Belangrijke informatie
-48.5%
Groei van de winst
-47.7%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 69.9% |
| Inkomstengroei | n/a |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 10 Jun 2024 |
Recente toekomstige groei-updates
Recent updates
Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost
Jun 13
Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce
Apr 28We're Keeping An Eye On InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Rate
Jul 11We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth
Jan 21We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth
Aug 31Here's Why We're Watching InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Situation
Mar 29InDex Pharmaceuticals Holding's (STO:INDEX) Shareholders Are Down 24% On Their Investment Over The Past Year.
Feb 04
How Much Are InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Insiders Spending On Buying Shares?
Dec 21Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 3/31/2024 | 108 | -56 | -49 | -49 | N/A |
| 12/31/2023 | 98 | -95 | -38 | -38 | N/A |
| 9/30/2023 | 98 | -46 | -25 | -25 | N/A |
| 6/30/2023 | 98 | -12 | -1 | -1 | N/A |
| 3/31/2023 | 1 | -123 | -134 | -134 | N/A |
| 12/31/2022 | 1 | -100 | -129 | -129 | N/A |
| 9/30/2022 | -2 | -67 | -139 | -139 | N/A |
| 6/30/2022 | -2 | -92 | -142 | -142 | N/A |
| 3/31/2022 | 0 | -113 | -134 | -134 | N/A |
| 12/31/2021 | 0 | -103 | -124 | -124 | N/A |
| 9/30/2021 | 3 | -90 | -88 | -88 | N/A |
| 6/30/2021 | 3 | -70 | -66 | -70 | N/A |
| 3/31/2021 | 0 | -43 | -58 | -57 | N/A |
| 12/31/2020 | 0 | -57 | -72 | -71 | N/A |
| 9/30/2020 | 0 | -73 | -98 | -97 | N/A |
| 6/30/2020 | 0 | -92 | -112 | -108 | N/A |
| 3/31/2020 | 0 | -95 | -89 | -89 | N/A |
| 12/31/2019 | 0 | -88 | -85 | -85 | N/A |
| 9/30/2019 | 0 | -84 | -71 | -71 | N/A |
| 6/30/2019 | 0 | -72 | -68 | -68 | N/A |
| 3/31/2019 | 0 | -81 | -74 | -74 | N/A |
| 12/31/2018 | 1 | -82 | -79 | -79 | N/A |
| 9/30/2018 | 0 | -82 | -73 | -73 | N/A |
| 6/30/2018 | 0 | -80 | -73 | -73 | N/A |
| 3/31/2018 | 0 | -69 | -72 | -72 | N/A |
| 12/31/2017 | 0 | -73 | N/A | -67 | N/A |
| 9/30/2017 | 0 | -67 | N/A | -83 | N/A |
| 6/30/2017 | 0 | -61 | N/A | -74 | N/A |
| 3/31/2017 | 0 | -56 | N/A | -64 | N/A |
| 12/31/2016 | 0 | -41 | N/A | -32 | N/A |
| 9/30/2016 | 0 | -31 | N/A | -11 | N/A |
| 6/30/2016 | 0 | -31 | N/A | -11 | N/A |
| 3/31/2016 | 0 | -29 | N/A | -14 | N/A |
| 12/31/2015 | 0 | -30 | N/A | -37 | N/A |
| 9/30/2015 | 0 | -33 | N/A | -42 | N/A |
| 6/30/2015 | 0 | -36 | N/A | -46 | N/A |
| 3/31/2015 | 23 | -25 | N/A | -27 | N/A |
| 12/31/2014 | 45 | -15 | N/A | -8 | N/A |
| 12/31/2013 | 1 | -68 | N/A | -116 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: INDEX is forecast to remain unprofitable over the next 3 years.
Winst versus markt: INDEX is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: INDEX is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: Insufficient data to determine if INDEX's revenue is forecast to grow faster than the Swedish market.
Hoge groei-inkomsten: Insufficient data to determine if INDEX's revenue is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if INDEX's Return on Equity is forecast to be high in 3 years time